I N T R O D U C T I O N
Since 2008, the US Food and Drug Administration (FDA) and other regulators have mandated that all new glucose-lowering agents undergo long-term cardiovascular outcome trials to demonstrate safety, primarily in response to concerns that drugs (notably rosiglitazone) that were effective in improving glycaemic control could increase cardiovascular risk [1] . Just over a decade later, almost 20 large-scale cardiovascular or kidney outcome trials have been completed, resulting in an explosion of evidence that has transformed diabetes care. Of the newer classes of glucose-lowering agents, sodium-glucose cotransporter 2 (SGLT2) inhibitors have been shown to consistently reduce the risk of clinically important, patient-level cardiovascular outcomes, including atherosclerotic cardiovascular events and hospitalization for heart failure (HF) [2] . The advent of SGLT2 inhibitors thus represents a major advance for individuals with type 2 diabetes mellitus (T2DM) and those who care for them.
The emergence of evidence for the SGLT2 inhibitor class has been watched with great anticipation in the nephrology community. It has been almost two decades since the benefits of renin-angiotensin system (RAS) blockade were confirmed in Irbesartan Diabetic Nephropathy Trial (IDNT) [3] and Reduction of Endpoints in Non-Insulin-Dependent Diabetes Mellitus with Angiotensin 2 Antagonist Losartan (RENAAL) [4] ; however, despite this, growth in the global burden of diabetic kidney disease (DKD) has continued unabated [5, 6] . The capacity of SGLT2 inhibitors to reduce albuminuria created hope for a clinically meaningful kidney benefit. This optimism was further reinforced by secondary analyses of the SGLT2 cardiovascular outcome trials, which demonstrated that these drugs consistently reduced the risk of serum creatinine-based kidney outcomes [7] [8] [9] [10] . However, most participants in these trials were at low risk of end-stage kidney disease (ESKD) and thus the effect of SGLT2 inhibitors on the most important patient-level kidney outcome-namely the need for dialysis or transplantation-was uncertain.
The Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial was designed to specifically address this evidence gap [11] . The trial demonstrated that an SGLT2 inhibitor, canagliflozin, substantially reduced the progression of DKD (doubling of serum creatinine, ESKD or cardiovascular or kidney-related death) in participants with T2DM and severely increased albuminuria who were already receiving RAS blockade. Indeed, CREDENCE demonstrated, for the first time ever, that a single intervention reduced the need for dialysis, transplantation or death due to kidney disease in its own right. A 2019 metaanalysis [12] synthesizing the accumulated trial evidence provided further strong support for the role of SGLT2 inhibition for kidney protection in people with T2DM and that the combination of RAS blockade and SGLT2 inhibition should be routinely offered to patients with T2DM who have, or are at high risk of, progressive kidney disease, with the strongest evidence for canagliflozin.
In the face of these clear and substantial benefits for cardiovascular and kidney outcomes, a number of other important questions remain. Who might benefit most from treatment? How should this evidence be applied in routine practice to maximize benefits and ensure potential harms are minimized? Are there other patient groups, aside from those with T2DM, who may benefit from SGLT2 inhibitors? Finally, how should these agents be used in combination with other currently available and future treatments? Some of these issues, including SGLT2 inhibition in people with type 1 diabetes and in people with non-DKD, have been examined in this special issue of NDT. In this analysis we explore how select patient characteristics and how concomitant drug use might influence the use of SGLT2 inhibitors in people with T2DM and chronic kidney disease (CKD), discuss current guidelines recommendations and explore future research priorities in this area.
SGLT2 inhibition across different levels of estimated glomerular filtration rate (eGFR)
The completed trials included participants with varying levels of baseline eGFR and albuminuria. In the three cardiovascular outcome trials, the proportion of participants with baseline eGFR <60 mL/min/1.73 m 2 ranged from 7.4 to 25.9% [8, 13, 14] . In contrast, 60% of participants in CREDENCE had a baseline eGFR <60 mL/min/1.73 m 2 . Most participants in the cardiovascular outcome trials had levels of albuminuria within the normal range at baseline [9, 15, 16] , whereas those in the CREDENCE trial were required to have a urinary albumin:creatinine ratio of at least 300 mg/g at enrolment. While protection against kidney failure with SGLT2 inhibitors other than canagliflozin remains to be demonstrated in the ongoing kidney outcome trials, the accumulated trial evidence has allowed for a robust assessment of the effects of SGLT2 inhibition in patients with T2DM across varying levels of eGFR and albuminuria.
The glucose-lowering effect of SGLT2 inhibitors is directly proportional to glomerular filtration, and thus glycaemic efficacy decreases substantially as kidney function declines [17] . Because regulatory approvals for these drugs have been primarily based on their ability to reduce glycated haemoglobin (HbA1c), SGLT2 inhibitors have largely not been approved for use in people with an eGFR <45 mL/min1.73 m 2 [18] . However, in the CREDENCE trial, the effect of canagliflozin on doubling of serum creatinine, ESKD or death due to kidney disease {hazard ratio [HR] 0.66 [95% confidence interval (CI) 0.53-0.81]} was consistent across all levels of kidney function down to an eGFR of 30 mL/min/1.73 m 2 . The effect of canagliflozin on cardiovascular death, non-fatal myocardial infarction or non-fatal stroke [HR 0.80 (95% CI 0.67-0.95)] was also not modified by baseline kidney function. While largely powered by the effects of canagliflozin observed in the CREDENCE trial, a recent meta-analysis [12] of the four major trials showed that SGLT2 inhibition reduces the risk of progression of kidney disease across all levels of kidney function studied to date, including 30% proportional risk reduction in people with an eGFR of 30-45 mL/min/1.73 m 2 , in whom the glucose-lowering effect is almost completely abrogated.
The disconnect between glucose lowering and effects on kidney and cardiovascular outcomes is a characteristic feature of SGLT2 inhibition. This is further supported by head-to-head data showing that canagliflozin slows the loss of kidney function compared with glimepiride [19] and that kidney benefits are independent of HbA1c before and during therapy, and by the degree of HbA1c lowering [20] .
Because the risk of ESKD and cardiovascular mortality increases substantially as eGFR declines [21, 22] , the absolute effects of treatment with SGLT2 inhibition are likely to be at least as large, if not greater, in patients with an eGFR <60 mL/ min/1.73 m 2 compared with those with preserved kidney function. In the CREDENCE trial, the estimated number of primary events prevented per 1000 patients treated over 2.6 years is substantially greater in participants with a starting eGFR <60 mL/ min/1.73 m 2 (Figure 1 ).
The accumulated trial evidence provides strong evidence that SGLT2 inhibition should be prioritized in people with T2DM and CKD, including those with a starting eGFR of 30-45 mL/min/1.73 m 2 . Importantly, in the CREDENCE trial, participants whose eGFR fell to <30 mL/min/1.73 m 2 continued on randomized treatment until dialysis or transplantation. As a result, the FDA now permits the continued use of canagliflozin with an eGFR <30 mL/min/1.73 m 2 until dialysis or transplantation in people already initiated on therapy [23] .
Impact of albuminuria
SGLT2 inhibition ameliorates albuminuria by approximately a third in patients with moderate or severely increased albuminuria, with lesser effects in those with normal albuminuria [15, 24] . If these drugs protect the kidney solely by lowering albuminuria as hypothesized, then people with higher levels of albuminuria should benefit more. However, a meta-analysis of the major SGLT2 inhibitor trials, which included CREDENCE, demonstrated that the proportional kidney benefits are consistent irrespective of baseline albuminuria [12] . Secondary analyses of the cardiovascular outcome trials also suggest that cardiovascular benefits might be similar across different levels of albuminuria [15, 16] .
The consistent evidence of kidney protection across the spectrum of albuminuria has important implications because the clinical phenotype and presentation of DKD have changed in recent decades [25] . Normoalbuminuric DKD is increasingly common; it is estimated that 40% of people with T2DM develop reduced kidney function without having albuminuria documented [26, 27] . While the risk of ESKD for these SGLT2 inhibition in CKD i49 individuals is low, progressive loss of kidney function can still occur [28] , with a heterogeneous range of structural changes on kidney biopsy [25] , suggesting that there are probably a number of different mechanisms of disease progression aside from classically progressive albuminuria. SGLT2 inhibition clearly reduces cardiovascular events and may reduce kidney events even in people with normal albuminuria and thus represents a promising therapeutic option for this patient population. Furthermore, T2DM with normal albuminuria is much more common than classically progressive DKD, therefore SGLT2 inhibition may be an important strategy for kidney (and cardiovascular) risk reduction at a population level. At the same time, because patients with substantially increased albuminuria are at much higher risk of ESKD, treatment with SGLT2 inhibitors in these individuals should be prioritized because the absolute benefits are greater (Figures 2 and 3 ; note the scale in Figure 2 is twice as wide as in Figure 1 ) [15] .
Stratification of risk based on atherosclerotic cardiovascular disease
The presence or absence of atherosclerotic cardiovascular disease has typically been used to stratify absolute cardiovascular risk and identify which patients should be treated with cardioprotective therapies (i.e. primary versus secondary prevention). While this may be a useful approach for the prevention of atherosclerotic vascular events in patients without CKD, this distinction is probably of limited use in patients with CKD. A 2018 meta-analysis of the cardiovascular outcome trials showed that benefits for HF and kidney disease progression are consistent irrespective of a history of atherosclerotic cardiovascular disease [2] . Because individuals with T2DM and CKD are at very high risk of both outcomes, treatment with SGLT2 inhibitors should be offered regardless, as suggested in the most recent clinical practice guidelines (discussed below). In CREDENCE, consistent protection against cardiovascular and kidney outcomes was observed for primary and secondary prevention cohorts [29] , further emphasizing that stratifying absolute risk based on the history of atherosclerotic cardiovascular disease alone is short-sighted, particularly in patients with T2DM and severely increased albuminuria, for whom the absolute risk of adverse outcomes is particularly high.
SGLT2 inhibition with and without RAS blockade
The CREDENCE trial provided strong evidence that kidney and cardiovascular protection with canagliflozin is achieved in addition to RAS blockade, as the use of RAS blockade was mandated for entry into the trial. In comparison, there is less data on whether SGLT2 inhibitor monotherapy is effective at slowing the progression of kidney disease, although subgroup data from the cardiovascular outcome trials appear promising. A meta-analysis of these trials found that kidney protection was consistent regardless of baseline use of RAS blockade, a finding limited somewhat by the fact all but 20% of participants were receiving RAS blockade [12] . Nevertheless, these data provide some justification for the use of SGLT2 inhibitors without background RAS blockade in certain patients, for example, those with normoalbuminuric DKD, for whom there is somewhat less data on kidney protection at lower levels of albuminuria [30] , or those experiencing hyperkalaemia, which occurs more frequently as kidney function declines [31] . Reassuringly, no increased risk of acute kidney injury, volume depletion or hyperkalaemia were observed in the CREDENCE trial, suggesting that the combined use of SGLT2 inhibition and RAS blockade should be well tolerated from a haemodynamic perspective, if used appropriately.
Concomitant diuretics: safe and effective?
The efficacy and safety of SGLT2 inhibitors in combination with diuretics are of particular clinical relevance because the use of diuretics becomes increasingly common as kidney function declines and because hypertension and HF are highly prevalent in patients with DKD [32, 33] . Concerns have been expressed about the potential for volume depletion with broad untargeted use of SGLT2 inhibitors, particularly, when used in conjunction with loop diuretics [34] . To minimize this risk, SGLT2 inhibitors should not be initiated in people with unstable volume status or those with hypovolaemia. Furthermore, loop diuretic dose should be adjusted appropriately (SGLT2 inhibitors are loop diuretic sparing). Subgroup analyses from the cardiovascular outcome trials suggest that the effects of SGLT2 inhibition on kidney and cardiovascular outcomes are mostly consistent in patients receiving and not receiving diuretics, and data from the EMPA-REG OUTCOME trial (NCT01131676) showed that diuretic use did not alter the risk of kidney or volume-related adverse events [7, 9, 35, 36] . However, the overall risk of adverse kidney outcomes in these trials was low, and corresponding data in a high-risk population, such as CREDENCE, will provide further important information.
Metformin and the question of first-line treatment
In almost all clinical practice guidelines, metformin remains the preferred first-line pharmacotherapy for T2DM, in large part due to its low cost, tolerability and safety. However, evidence for cardiovascular and kidney benefits with new glucose-lowering agents has led to some debate about metformin's place as first-line treatment for all patients [37] , especially since its effects on cardiovascular outcomes are not clear [38] , with little direct evidence for kidney outcomes. Most recently, joint guidelines from the European Society of Cardiology (ESC) and European Association for the Study of Diabetes (EASD) suggest SGLT2 inhibitors and glucagon-like peptide-1 (GLP-1) agonists should be used in patients with T2DM who have or are at high risk of cardiovascular disease, whether they are treatment naïve or already receiving metformin [39] . In the EMPA-REG OUTCOME trial, compared with participants receiving metformin, the effects on cardiovascular death and on hospitalization for HF were at least as large in participants not on metformin [36, 40] , but otherwise there are currently scant data on the effects of SGLT2 inhibitors with and without metformin. Absolute benefits, possible adverse effects, reimbursement and out-of-pocket costs would all be important to consider if SGLT2 inhibitors are to be used as first-line oral therapy.
Latest guideline recommendations on the use of SGLT2 inhibitors
Several major clinical practice guidelines have been updated in the past 18 months to reflect the evolving evidence for cardiovascular and kidney protection from SGLT2 trials. Major updates include a joint consensus report from the American Diabetes Association (ADA) and the EASD, and the ADA Standards of Care [41, 42] . These have been accompanied by a number of statements from other organizations including the American College of Cardiology, ESC, American Association of Clinical Endocrinologists, Diabetes Canada and European Renal Association-European Dialysis and Transplant Association [39, [43] [44] [45] [46] .
Most noticeably, guidelines now recommended the selection of agents based on end-organ protection and patient comorbidities. Most guidelines recommend either SGLT2 inhibitors or GLP-1 receptor agonists as second-line treatment (after metformin) in people with T2DM and a history of atherosclerotic cardiovascular disease (i.e. for the secondary prevention of cardiovascular events). The ESC-EASD guidelines recommend either an SGLT2 inhibitor or GLP-1 receptor agonist in people with T2DM at high or very high risk of cardiovascular disease, irrespective of whether they are treatment naïve or already on metformin.
Given the consistent evidence that SGLT2 inhibition can reduce the risk of hospitalization for HF and kidney disease progression, the ADA-EASD consensus report also recommends the use of SGLT2 inhibitors in people with T2DM and HF or CKD (irrespective of a history of atherosclerotic cardiovascular disease). Based on the results of the CREDENCE trial, the updated 2019 ADA Standards of Care specifically endorse the use of SGLT2 inhibitors for the prevention of kidney failure, cardiovascular events or both in patients with an eGFR >30 mL/min/1.73 m 2 , particularly in those with severely increased albuminuria (Grade A recommendation) [47] .
Implementation of evidence into clinical practice
There is strong evidence from completed trials that patients with T2DM and CKD are among those who are likely to benefit most from SGLT2 inhibition, with larger absolute risk reductions for those with reduced kidney function and higher levels of albuminuria (Figures 1 and 2) . The strongest evidence for kidney protection is with canagliflozin, and while data from cardiovascular outcome trials of other SGLT2 inhibitors are promising, a class effect on patient-level kidney outcomes (i.e. dialysis or transplantation) remains to be demonstrated in ongoing kidney outcome trials. Nevertheless, there is currently limited evidence that key patient characteristics or use of concomitant drugs modifies the efficacy or safety of SGLT2 inhibition ( Table 1) , supporting that these drugs should be routinely offered to most patients with T2DM and CKD.
Collaborative efforts from the nephrology community and other stakeholders are now required to ensure that findings from randomized trials are translated into routine clinical practice. In this respect, initiatives such as the Diabetic Kidney Disease Collaborative (DKD-C) are welcome. The DKD-C was recently launched by the American Society of Nephrology to increase coordination between primary care, nephrologists and other specialties to deliver optimal care to people with diabetes and CKD. Current data suggest that a substantial proportion of patients with CKD who would benefit from treatment with RAS blockade still do not receive it [48] . As such, implementation research should be a priority to speed the incorporation of SGLT2 inhibitors and other proven therapies into clinical practice for the benefit of patients.
Looking to the future
With the growing number of therapeutic options for people with T2DM, there is a need to better understand the optimal combination of treatments. There is strong evidence that GLP-1 receptor agonists also reduce the risk of a range of cardiovascular events [49] . The types of events prevented with GLP-1 receptor agonists, and time frames over which benefits accrue, highlight that the mechanism of cardioprotection with these agents is likely to be distinct from SGLT2 inhibitors and mediated mainly through anti-atherothrombotic effects. In contrast, SGLT2 inhibitors have greater benefits on HF and kidney outcomes, underscoring their unique haemodynamic effects. Additionally, GLP-1 receptor agonists are permitted for use down to an eGFR of 15 mL/min/1.73 m 2 in some regions, presenting an important treatment option for patients with advanced CKD. The contrasting mechanisms and benefits of these two classes of drugs raise the possibility that combination therapy with GLP-1 receptor agonists and SGLT2 inhibitors could provide additive cardiovascular and kidney benefits. Short-term trials of semaglutide and dulaglutide suggest that combination treatment reduces HbA1c and body weight to a greater extent than SGLT2 inhibition alone, without additional safety concerns [50, 51] . However, randomized evidence on patient-level cardiovascular and kidney outcomes is currently lacking and a trial designed to test these agents in combination would be very valuable. In lieu of such trials, the uptake of SGLT2 inhibitors in routine clinical practice will mean that future randomized studies, including of GLP-1 receptor agonists, may well include substantial numbers of participants receiving SGLT2 inhibitor therapy, and thus provide indirect evidence on the effects of these drug classes used in combination. Most recently, the results of the first dedicated HF outcome trial of an SGLT2 inhibitor, DAPA-HF (dapagliflozin; NCT03036124), were presented at the 2019 ESC Congress. DAPA-HF is notable because it is the first SGLT2 inhibitor trial enrolling participants with and without T2DM. In this trial, the effect on the primary outcome of urgent HF visit, hospitalization for HF or cardiovascular death [HR 0.74 (95% CI 0.65-0.85)] was similar in participants with and without T2DM [52] , further strengthening the hypothesis that these drugs may also benefit individuals with non-diabetic CKD. Likewise, DAPA-CKD and EMPA-KIDNEY are also enrolling participants without T2DM, and thus are expected to provide important evidence on the effects of SGLT2 inhibition on kidney outcomes in people without diabetes [53, 54] . These trials also include participants with a starting eGFR as low as 20 mL/min/1.73 m 2 and thus may potentially provide some important information in people with advanced CKD.
C O N C L U S I O N
SGLT2 inhibitors are undoubtedly a practice-changing development for patients with T2DM and CKD. Evidence from completed trials strongly supports the role of SGLT2 inhibition to prevent kidney and cardiovascular events in patients with T2DM, and those with lower levels of eGFR and higher levels of albuminuria are among those who stand to gain the greatest absolute benefits. 
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